A phase I trial of recombinant human interferon-γ in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS)

Journal of Clinical Immunology

Volumn 9, Issue 4, 1989, Pages 351-361

  Lane, H Clifford ^a   Davey Jr , Richard T ^a   Sherwin, Stephen A ^b   Masur, Henry ^c   Rook, Alain H ^d   Manischewitz, Jody F ^e   Quinnan, Gerald V ^e   Smith, Phillip D ^c   Easter, Margaret E ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GENENTECH INC   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

human immunodeficiency virus (HIV); Interferon ; Kaposi's sarcoma; pharmacokinetics

Indexed keywords

GAMMA INTERFERON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; BLOOD LEVEL; CLINICAL ARTICLE; DRUG TOXICITY; FEVER; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPOSI SARCOMA; LEUKOPENIA; MALE; NATURAL KILLER CELL; NAUSEA; SIDE EFFECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; CYTOMEGALOVIRUS; CYTOTOXICITY, IMMUNOLOGIC; DRUG EVALUATION; HUMAN; INTERFERON-GAMMA, RECOMBINANT; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; MALE; MIDDLE AGE; SARCOMA, KAPOSI;

EID: 0024441238     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/BF00918667     Document Type: Article

References (37)

1. Pharmacokinetic study of partially pure γ-interferon in cancer patients
2. A phase I trial of recombinant gamma interferon in patients with cancer
3. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant γ-interferon in cancer patients
4. The acquired immunodeficiency syndrome: An update
5. Immunologic developments in AIDS-1985
6. Preliminary observations on the effect of recombinant leukocyte α interferon in homosexual men with KS
7. Human interferon as a therapeutic agent: A decade passes
8. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome
9. Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome: Clinical response and prognostic parameters
10. Anti-retroviral effects of interferon-α in AIDS-associated Kaposi's sarcoma
11. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma
12. Interferon-gamma, the activated macrophage, and host defense against microbial challenge
13. Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome
14. Activation of tissue macrophages from AIDS patients: In vitro response of AIDS alveolar macrophages to lymphokines and interferon-γ
15. Patients at risk for AIDS-related opportunistic infections: Clinical manifestations and impaired gamma interferon production
16. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome
17. In vitro and in vivo activation of human mononuclear phagocytes by interferon-γ: Studies with normal and AIDS monocytes
18. Interferons and antiviral activity
19. Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents
20. Direct and cell-mediated effects of interferon-α and -γ on cells chronically infected with HTLV-III
21. Phase I trial of recombinant interferon gamma by 1-hour infusion
22. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon
23. Phase I trial of recombinant interferon gamma in cancer patients
24. Atopic manifestations in the acquired immune deficiency syndrome: Response to recombinant interferon gamma
25. Natural human interferon-gamma: Complete amino acid sequence and determination of sites of glycosylation
26. Convenient assay for interferons
27. Revision of the case definition of acquired immunodeficiency syndrome for national reporting—United States
28. Reporting results of cancer treatment
29. Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome
30. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome
31. Human host response to Giardia lamblia: Spontaneous killing by mononuclear leukocytes in vitro
32. Herpesvirus infections in the acquired immune deficiency syndrome
33. Immunologic reconstitution in the acquired immunodeficiency syndrome
34. Antiretroviral therapy and immunologic reconstitution in AIDS
35. Effect of intravenous recombinant γ-interferon on the respiratory burst of blood monocytes from patients with AIDS
36. Treatment of AIDS-related Kaposi's sarcoma with recombinant γ-interferon